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Abstract
Chromium(III) is one of the most controversial biometals. Although, it is no longer on the list of minerals necessary for the proper
functioning of the human body, and its pharmacological effect is still under discussion. One of the purposes of Cr(III) administration
is to use it in patients with mood disorders and it is strictly related to its pharmacological, not dietary effect. This is because its high
doses are necessary to obtain the results and additionally, no deficiencies in human population have been noted. In this study, the
affinity of chromium(III) to selected receptors and transporters in the rat brain was evaluated, and the effect of the 14-day
administration of this metal was assessed on the density of selected receptors. All analyses were performed in vitro using radioligand
binding assays, and the results indicated lack of affinity to β1 and α1 receptors and serotonin transporter (SERT), furthermore very
weak affinity to the 5-HT1A receptor (30% inhibition at 10
−4 and 10−5 M). Analysis of the α1 and β1 adrenergic receptor density
indicated lack of any adaptive effects after 14 days of Cr(III) administration through intraperitoneal injections (doses 6 and
12 mg/kg). The antidepressant activity of chromium(III) indicated in clinical trials concerned patients with atypical, seasonal, or
dystonic symptoms. This effect, as it seems based on the presented results, does not depend on direct affinity to serotonin receptors
and transporter nor is the result of adaptive changes in the adrenoreceptor system.
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Introduction
Currently, chromium(III) is probably the most controversial
biometal, and concepts about its role are still changing. In
2014, it was removed from the list of micronutrients [1].
Since then, the evidence that Cr(III) is not a micronutrient
have multiplied [2, 3].
The basic biological properties of Cr(III) relate to its activi-
ties in the metabolism of carbohydrates [4], which, apart from
the use in supplementation of patients in various states of im-
paired glucose utilization, allows using Cr(III) supplementation
in patients with PCOS [5]. Other directions of usage were also
indicated in available literature. The possibility of influencing
the dynamics of the development of cognitive disorders [6],
post-stroke protective action [7], and the possibility of using
or strengthening the pharmacotherapy of depression, especially
atypical, was investigated [8–12]. The first postulates indicating
the possibility of antidepressant effect of Cr(III) were
established in 1994 [8, 9]. As it was shown in studies using
behavioral tests (a modified swimming test in rats and mice)
[13–15] and animal models of depression [16], this is due in
varying degrees to effects on noradrenergic, dopaminergic, se-
rotonin, and GABAergic receptors.
The results of the available research are not consistent.
Piotrowska et al. [15], in contrast to the results of Khanam
and Pallai [13], indicate the participation of the noradrenergic
pathway in the antidepressant action of Cr(III). Studies in the
mouse model have shown that this activity is partially depen-
dent on the 5-HT1A and 5-HT2A receptors [14] and the dopami-
nergic system [15]. On the other hand, the noradrenergic mech-
anism was indicated by antagonism of Cr(III) action caused by
combined administration with adrenergic receptor antagonists
(propranolol, prazosin, yohimbine) and augmentation of
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reboxetine action [15]. It was also conveyed in studies by
Franklin and Odontiadis [17] and Attenburrow et al. [18], where
higher serotonin levels and downregulation 5-HT2A serotonin
receptors have been shown. The participation of the glutamater-
gic system (AMPA and NMDA receptors) in the FST test in
mice was demonstrated by Piotrowska [14]. Khanam and Pillai
[13] suggested the involvement of the K+ channel. Prof.
Khanam’s group also indicates that chromium may have
an anxiolytic effect and is the consequence of the acti-
vation of the serotonin pathway [19]. In addition, a
decrease in the concentration of corticosterone in the blood
plasma of animals subjected to chronic unpredictable mild
stress was observed [16].
Clinical observations of the antidepressant action of
chromium(III) salts concern primarily atypical depression,
premenstrual syndrome (PMS) and premenstrual dysphoric
disorder (PDD), seasonal affective disorders (SAD), and cir-
cadian mood swings [10, 11]. This profile of activities is in-
teresting, and range of impact is slightly different for most
current antidepressants.
The influence of chronic Cr(III) administration on the den-
sity of brain receptors has not been indicated so far.
Chromium(III) affinity to these structures has not been stud-
ied. Therefore, the aim of the study was to determine the
affinity of Cr(III) to selected receptors and transporters in rat
brain and to evaluate the effect of chronic administration of
this salt on the density of β1-adrenergic and α1-adrenergic
receptors.
Materials and Methods
All procedures were approved by the Local Ethical
Committee of the Jagiellonian University Medical College,
Kraków (112/2009). The experiments were carried out on
adult male Wistar rats (180–250 g). The animals were housed
under conditions with constant temperature (20–22 °C), a con-
trolled 12:12 light-dark cycle and free access to standard
pellet diet and tap water. Each experimental group consisted
of 10 animals.
Imipramine (15 mg/kg, Sigma-Aldrich, Germany) and
chromium(III) trichloride (CrCl3 × 6 H2O; 6 mg/kg and
12 mg/kg, Sigma-Aldrich, Germany) were administered ip
everyday between 9.00 and 11.00 a.m. for 14 days. All com-
pounds were dissolved in 0.9% saline. Control group of ani-
mals received an ip injection of saline (vehicle). The volume
of vehicles or drug solutions for ip administrations was 2 ml/
kg. Doses of chromium(III) were expressed per elemental Cr
and selected on the basis of Franklin and Odontiadis research
and were recalculated due to the use of other salts [17]. In
connection with intraperitoneal administration, the dose esti-
mation did not consider differences in oral absorption of
chromium(III) chloride and chromium(III) picolinate.
Twenty-four hours after the last injection, rats were killed
by decapitation. The cortex and hippocampus separately were
rapidly removed from the brain, placed on dry ice, and then
transferred into a − 80 °C freezer until use.
Radioligand Binding Assay
β1-Adrenergic Receptors: Saturation and Inhibition
Experiments
Rat cerebral cortex was homogenized in 20 volumes of ice-
cold Tris-HCl buffer, pH = 7.6 in 25 °C using Ultra Turrax
T25B homogenizer (IKA) and centrifuged at 20,000g for
20 min. After decantation of the supernatant, the pellet was
resuspended in 20 volumes of buffer and centrifuged again in
the same conditions.
Samples consisted of 240 μl of the tissue suspension
(10 mg of wet weight), 30 μl of [3H]CGP-12177 (4-[3-[(1,1-
dimethylethyl)amino]2-hydroxypropoxy]-1,3-dihydro-2H-
benzimidazol-2-one hydrochloride, β1/β2 antagonist) in con-
centrations ranged from 0.03 to 3 nM were used to estimate
the density of β1-adrenergic receptors. The inhibition experi-
ments were performed in the same conditions but the concen-
tration of radioligand was 0.2 nM.
To evaluate non-specific and total binding, 1 μM propran-
olol and buffer were used respectively. Samples in duplicate
were incubated in 37 °C for 60 min. The incubation was fin-
ished by rapid filtration through Whatman GF/C filters and
washed using a 96-well FilterMate Harvester (Perkin Elmer,
USA). Radioactivity was measured using MicroBeta
TriLux—liquid scintillation counter (Perkin Elmer). The pro-
tein concentration was estimated using Bradford reagent.
α1-Adrenergic Receptors: Saturation and Inhibition
Experiments
Rat cerebral cortex was prepared according to previous pro-
cedure. Incubation mixture consisted of 240 μl of the tissue
suspension (10 mg of wet weight), 30 μl of 0.186–3.5 nM
[3H]prazosine, and 30 μl of buffer or 10 μM phentolamine
to estimate total and non-specific binding respectively. For
inhibition experiment, the concentration of radioligand was
0.2 nM.
Samples in duplicate were incubated for 30 min in 25 °C,
filtered rapidly through Whatman GF/B filters, and washed
with ice-cold buffer. Radioactivity was measured using
MicroBeta scintillation counter (Perkin Elmer).
5-HT1A Serotonergic Receptors: Inhibition Experiments
Rat hippocampi were homogenized in 20 volumes of ice-cold
Tris-HCl buffer (pH = 7.7 in 25 °C). The homogenate was
centrifuged in 10,000g for 10 min. Pellet was resuspended,
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incubated in 37 °C for 10 min, and centrifuged again.
Reaction mixture consisted of 30 μl of 0.01 mM or 0.1 mM
CrCl3, 30 μl of 1 nM [
3H]8-OH-DPAT ((±)-8-hydroxy-2-
dipropylaminotetralin hydrobromide, selective 5-HT1A ago-
nist), and 240 μl of tissue suspension (5 mg wet weight/ml)
was incubated in 37 °C for 20min. Incubation was finished by
rapid filtration through Whatman GF/B filters and wash-
ing with Tris-HCl buffer. All assays were performed in
duplicate. A total of 10 μM serotonin was used to estimate
non-specific binding.
Testing the Affinity of Chromium(III) to the Serotonin
Transporter (5HT-T)
Rat cortex was homogenized in 20 volumes of ice-cold Tris-
HCl buffer pH = 7.7 containing 120 mMNaCl and 5 mMKCl
and centrifuged in 20,000g for 20min. Pellet was resuspended
and centrifuged twice in the same conditions. Reaction mix-
ture consisted of 30 μl of 0.1 or 1 mM CrCl3 and 30 μl of
1 nM [3H]citalopram, and 240 μl of tissue suspension was
incubated in RT for 1 h. Rapid filtration and washing with
buffer were performed through Whatman GF/B filters. All
assays were performed in duplicate.
Statistical Analysis
The results were analyzed in GraphPad Prism 4, submitted as
means ± standard deviations. The type of distribution was
tested using the Shapiro-Wilk test; to detect outliers, the
Grubbs test was used. Differences between groups, while
meeting the requirements for the chosen test, were examined
by a one-way analysis of variance using the Dunnet test as the
post hoc test. The significance level α = 0.05 was assumed.
Results
Analysis of chromium(III) affinity to selected receptors and
transporters as a pilot study was performed in two points using
high concentrations of the examined biometal (10−3–10−5). At
selected concentrations, Cr(III) did not bind (α1, β1) or was
bound extremely weakly (5-SERT, 5-HT1A). The results are
shown in Table 1.
The results of the saturation tests were subjected to one-
way analysis of variance, and the presence of statistically sig-
nificant differences in β-receptor density in the cortices of the
rats subjected to 14 days of treatment (F(3,16) = 4723; p =
0.0152). The tissues of imipramine-treated animals showed a
reduced density of β-receptors (p < 0.05). Tissues of animals
receiving chromium(III) salts in both doses (6 and 12 mg/kg)
did not differ significantly from control tissues (Figs. 1 and 2).
Alpha1 receptor density analysis after 14 days of therapy is
shown in Fig. 3. The examined cortex did not show
statistically significant differences (F(3.16) = 0.03259 p =
0.9918). Figure 4 is an example of the result.
Discussion
Understanding the mechanism of action of the antidepressant
drug may indicate the research direction (new, or already test-
ed and partially confirmed) for sources of disease, which, in
the case of depression, is still the current topic. The association
of a clinical picture that for depression may be inhomoge-
neous with the neurobiological mechanism of action of an
antidepressant may allow the selection of a group of patients
who are more likely to react properly to the prescribed drug.
Clinical trials with the use of Cr(III) supplementation were
used in patients with seasonal affective disorder, associated
with the menstrual cycle, atypical depression, and dysthymia
[10–12, 20, 21]. Patients responded favorably to monotherapy
[12] and as augmentation of therapy [20].
In this study, the affinity of chromium(III) to selected re-
ceptors and transporters was examined, which is used as a
screening method for assessing the suitability of new psychi-
atric treatments and the effect of chronic administration on the
Table 1 Percentage of inhibition of a labeled ligand from its specific
ligand-receptor complex
Receptor Radioligand Cr concentration [M] % of inhibition
SERT [3H]citalopram 10−3 3%
10−4 0%
5-HT1A [
3H]8-OH-DPAT 10−4 30%
10−5 30%
β1 [
3H]CGP-12177 10−3 0%
10−4 0%
α1 [
3H]prazosin 10−3 0%
10−4 0%
Fig. 1 Beta-adrenergic receptor density in frontal cortex of rats after
chronic administration of chromium (Cr 6 in dose 6 mg/kg or Cr 12 in
dose 12 mg/kg) or imipramine (IMI) expressed as the femtomole per
milligram of protein. The result is given as mean ± SEM (n = 5).
#p < 0.05 vs. control group (NaCl). Post hoc test: Dunnet
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density of selected receptors in the cortex and hippocampus,
and can be considered as an indicator of possible antidepres-
sant effect. In our analyses, we have indicated that Cr(III) has
no affinity to α1 and β1 adrenergic receptors.
Activity to α1 and β1 adrenoreceptors is not an intentional
mechanism of action of antidepressants. It can also cause side
effects. Lack of direct affinity to the α1 receptors may indicate
that Cr(III) will not cause excess sedation, which has never
been indicated as an adverse effect when using supplements
with this metal [10–12, 20, 21]. On the other hand, blocking
the α1 adrenoceptor may contribute to development of
adaptative changes such as up-regulation, and thus changes
desired from a therapeutic point of view.
The role of noradrenaline in the pathophysiology of depres-
sion has been repeatedly confirmed [for review: 22]. The in-
dividual receptors of the noradrenergic system differ in their
function in the aspect of the mechanism of action of antide-
pressants. Blockade ofα1 receptors mimics the symptoms of a
depressive state (which, like chronic stress, may be associated
with desensitization of these receptors) [23]. Some antidepres-
sants show high affinity to the α1 receptors (amitriptyline,
mianserin) and α2 (doxepin, imipramine, mirtazapine, or nor-
triptyline), which is their characteristic feature after single ad-
ministration. Completely different effects occur after chronic
administration. Such therapy, like repeated electroconvulsive
treatments, increases the density of α1 receptors in the frontal
cortex and hippocampus [22, 24], while the number of α2
receptors decreases [22, 25].
Adaptive changes ofα1 and β1 receptors have been repeat-
edly used as one of the markers of antidepressant activity of
newly discovered drugs. The first detected adaptive change
was β-downregulation [26]. This effect is also caused by elec-
troconvulsive shock (ECS) and most antidepressants (TCAs,
MAOIs) except for SSRI, for which results are mixed [27]. In
the noradrenergic system, up-regulation of the α1 receptors is
also observed. This phenomenon has been confirmed by be-
havioral and electrophysiological studies and is caused by a
variety of antidepressants [28–31] and ECS [24]. Currently
used drugs (e.g., SSRI) do not give adaptive changes to ad-
renergic receptors.
Analysis of the density of selected receptors in the frontal
cortex of the rats, after chromium(III) chloride administered at
doses of 6 and 12 mg/kg for 2 weeks, gave negative results. In
the examined tissues, there was no reduction in the density of
β-receptors nor was there any increase in the density of α1
receptors. It is known that not all drugs with clinically proven
antidepressant activity change the density of adrenergic corti-
cal receptors (e.g., SSRIs do not induce β-downregulation).
Binding to serotonin receptors and serotonin transporter
gave rise to several clinically useful groups of antidepressants.
Unlike the earlier TLPD, SSRIs acted to raise levels of sero-
tonin without increasing norepinephrine levels. The most
drug-effective in this group is escitalopram. Its precursor,
citalopram, has the properties of the most selective inhibitor
of the serotonin transporter and the use of only one of the
enantiomers further improved the selectivity [32].
In animal models, it was found that inhibition of SERT as
well as the 5-HT1B receptor increases the serotonin concentra-
tion in the prefrontal cortex, while agonists of this receptor
Fig. 3 Density of α1-adrenergic receptors in the cortex of rats after
chronic administration of chromium (Cr 6 in dose 6 mg/kg or
Cr 12 in dose 12 mg/kg) or saline (NaCl). The result is given as
mean ± SEM (n = 5)
Fig. 2 A representative result of saturation analysis for β-receptors. IMI
imipramine, NaCl saline, Cr 6 chromium chloride in dose 6 mg/kg, Cr 12
chromium chloride in dose 12 mg/kg
Fig. 4 A representative of the saturation analysis for α1-receptor. NaCl
saline, Cr 6 chromium chloride in dose 6 mg/kg, Cr 12 chromium
chloride in dose 12 mg/kg
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increase the rate of firing of serotonergic neurons in the raphe
nucleus [33]. This research direction allows new drugs
to be introduced into the clinic, e.g., vortioxetine [34].
In presented study on the affinity of Cr(III) to selected
receptors and transporters, no affinity to SERT,α1, andβ1 was
found; very poor activity was determined in relation to the 5-
HT1A receptor.
5-HT1A are metabotropic receptors coupled to Gi/o
proteins. Their activation lowers cyclic adenosine
monophosphate (cAMP) concentration that leads to the
inhibition of neuronal activity. 5-HT releasing is regulated
by 5-HT1A autoreceptors by the negative feedbackmechanism
in nuclei neurons. 5-HT1A autoreceptors are associated with
the pathophysiology of anxiety behavior. SSRI treatment in-
creases 5-HTconcentration in synaptic cleft leading to chronic
activation of autoreceptors and in consequence to their desen-
sitization. After several weeks, it effects in further alterations
in the firing rates of the serotonergic neurons [35]. Mice with
low 5-HT1A autoreceptor expression are more sensitive to
stress and respond to SSRI treatment faster than mice with
higher expression of these receptors [36]. Authors show that
raphe 5-HT1A autoreceptors have negative influence on 5-HT
release. In our research, the affinity of Cr(III) to the 5-HT1A
receptors has been indicated, but in the hippocampus, where
they act as postsynaptic receptors.
Postsynaptic 5-HT1A are heteroreceptors located in amyg-
dala, hippocampus, septum, thalamus, and hypothalamus
and response to 5-HT released in these regions [37–39].
There are several lines of evidence that 5-HT1A
heteroreceptors are involved in the behavioral response to
antidepressant treatment. SSRIs are not active in NSF
(novelty-suppressed feeding) test in 5-HT1A knockout
mice. In wild-type mice, the behavioral effect of antide-
pressants in NSF test occurs after chronic treatment with
5-HT1A agonist—8-OH-DPAT. Administration of 8-OH-
DPAT exerts antidepressant-like influence on adult hippo-
campal neurogenesis [40].
The studies of Samuels et al. [38] showed that deletion of
5-HT1A receptors from mature dentate gyrus granule cells
abolished the behavioral effect of the fluoxetine in mice. The
neurogenesis and expression of hippocampal neurotrophic
factor (BDNF and VEGF) as a result of SSRI administration
were attenuated in mice lacking 5HT1A receptors. Certain
metals appear to affect the expression of BDNF (zinc, magne-
sium) [41, 42]. Such actions for chromium(III) have not been
confirmed yet.
The use of Cr(III) in the therapy of psychiatric disorders
concerns disorders with a complex manifestation. For today,
the mechanism of positive effect of supplementation with
this metal remains unclear. However, one should exclude
direct action on the receptors of the serotonergic and
noradrenergic systems and generation of adaptive changes
in the latter system.
Conclusions
Chromium(III) after 14 days of administration did not cause
adaptive changes within the α1 and β1 receptors in rat’s brain.
The ions of this metal have no affinity to the α1 and β1 recep-
tors. The tested biometal has no affinity to the serotonin trans-
porter (SERT) and the affinity of chromium(III) to the 5-HT1A
receptors is very low.
Limitations
In this experiment, intraperitoneal injection was used due to
the fact that chromium(III) chloride is absorbed very poorly
form the gut. Data on the penetration of this metal through the
blood–brain barrier is limited. The main limitation of this
work is lack of brain Cr(III) level estimations.
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